Prestige Consumer Healthcare (NYSE:PBH – Get Free Report) was downgraded by analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a research report issued on Monday,Zacks.com reports.
A number of other research firms have also weighed in on PBH. Oppenheimer lowered shares of Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a research report on Thursday, May 14th. Canaccord Genuity Group dropped their price objective on Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating on the stock in a research note on Friday, May 15th. Weiss Ratings cut Prestige Consumer Healthcare from a “hold (c)” rating to a “hold (c-)” rating in a research note on Thursday, May 14th. Finally, Jefferies Financial Group dropped their price objective on Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating on the stock in a research note on Friday, January 30th. Two investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $70.75.
View Our Latest Stock Report on Prestige Consumer Healthcare
Prestige Consumer Healthcare Stock Down 0.2%
Prestige Consumer Healthcare (NYSE:PBH – Get Free Report) last announced its quarterly earnings results on Wednesday, May 13th. The company reported $1.23 EPS for the quarter, missing analysts’ consensus estimates of $1.39 by ($0.16). Prestige Consumer Healthcare had a net margin of 17.48% and a return on equity of 11.54%. The business had revenue of $281.62 million during the quarter, compared to the consensus estimate of $293.64 million. During the same period in the previous year, the business posted $1.32 EPS. The firm’s revenue was down 5.0% on a year-over-year basis. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.420-4.510 EPS. As a group, equities research analysts predict that Prestige Consumer Healthcare will post 4.43 earnings per share for the current year.
Insiders Place Their Bets
In other Prestige Consumer Healthcare news, VP Jeffrey Zerillo sold 1,207 shares of the firm’s stock in a transaction that occurred on Tuesday, May 5th. The shares were sold at an average price of $54.99, for a total value of $66,372.93. Following the completion of the sale, the vice president directly owned 42,820 shares in the company, valued at $2,354,671.80. This trade represents a 2.74% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 1.40% of the stock is currently owned by company insiders.
Institutional Investors Weigh In On Prestige Consumer Healthcare
Several institutional investors have recently bought and sold shares of the company. Lido Advisors LLC boosted its stake in Prestige Consumer Healthcare by 5.4% in the fourth quarter. Lido Advisors LLC now owns 3,778 shares of the company’s stock valued at $235,000 after acquiring an additional 192 shares in the last quarter. Profund Advisors LLC boosted its stake in Prestige Consumer Healthcare by 3.2% in the third quarter. Profund Advisors LLC now owns 6,770 shares of the company’s stock valued at $422,000 after acquiring an additional 207 shares in the last quarter. Cerity Partners LLC boosted its stake in Prestige Consumer Healthcare by 5.9% in the second quarter. Cerity Partners LLC now owns 3,884 shares of the company’s stock valued at $310,000 after acquiring an additional 218 shares in the last quarter. UMB Bank n.a. boosted its stake in Prestige Consumer Healthcare by 110.1% in the fourth quarter. UMB Bank n.a. now owns 418 shares of the company’s stock valued at $26,000 after acquiring an additional 219 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd boosted its stake in Prestige Consumer Healthcare by 69.8% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 574 shares of the company’s stock valued at $35,000 after acquiring an additional 236 shares in the last quarter. 99.95% of the stock is currently owned by institutional investors and hedge funds.
About Prestige Consumer Healthcare
Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.
Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).
Featured Articles
- Five stocks we like better than Prestige Consumer Healthcare
- Block’s Pivot to Profits and AI Is Turning Heads
- HIVE Weaponizes Power for an AI Pivot
- A Deep Dive Into NVIDIA’s Latest Portfolio Moves
- Brady Corp Wires Up a Massive AI-Powered Breakout
Receive News & Ratings for Prestige Consumer Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prestige Consumer Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.
